Clinical Trial Update: Upadacitinib for Prurigo Nodularis [Phase 4]

View source ↗

Summary

Upadacitinib is being studied in Phase 4 for Prurigo Nodularis and is currently recruiting; sponsor is Psoriasis Treatment Center of Central New Jersey.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prurigo Nodularis

Drugs mentioned

• RINVOQ (Upadacitinib)

Snippet

Sponsor: Psoriasis Treatment Center of Central New Jersey | Conditions: Prurigo Nodularis | Phase 4 | Status: RECRUITING